The guanylate cyclase stimulator vericiguat: Insights and adverse events from a FAERS-based pharmacovigilance study
Our analysis provides a comprehensive safety assessment of vericiguat. Most of these results align with findings from previous studies. In addition, our data revealed several new adverse events. This study provides valuable insights that can inform future research and clinical practice.
Authors
- Bing Lv (ORCID: https://orcid.org/0000-0002-3356-027X)
- Jiming Han (ORCID: https://orcid.org/0000-0003-0026-3241)
- Qianying Li (ORCID: https://orcid.org/0000-0002-9139-7036)
- Yuan Hu
- Kehan Li
- Jia Tang
Publication Details
- Journal
- International Journal of Clinical Pharmacology and Therapeutics
- Published
- 2025-12-30
- DOI
- https://doi.org/10.5414/cp204875
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00